Merck has opened a 2,000-square-metre BioReliance testing facility at its headquarters in Darmstadt, Germany. The site provides commercial drug substance, drug product release, and Good Manufacturing Practice (GMP)-compliant stability testing for biopharmaceutical companies in Europe.

• Testing Services: The facility supports commercial drug substance and drug product release testing, alongside GMP-compliant stability studies for biologics, including monoclonal antibodies and cell therapies.
• Facility Operations: The new site is operational as part of Merck’s global BioReliance testing network and is expected to expand staffing over the coming years to support customer demand.
• Operational Scope: The facility is designed to help biopharmaceutical companies meet European regulatory requirements for in-region drug substance and drug product release testing and stability studies.

This summary is based on a news article published by BioSpectrum Asia.

About Ehub365

For Corporate Clients, ehub365 division delivers critical insights into the ASEAN medical sector, covering investments, new services, and practitioner news. 

A member of 365Asia. Our additional group services are Health365, 365Asia, 健康365, 365Sehat, and 365MEC.